Data Quality in Pharmacovigilance: Why It Is Crucial

Introduction 

Pharmacovigilance (PV) depends on one fundamental resource: reliable safety data. 

Every Individual Case Safety Report (ICSR), safety signal, Periodic Benefit-Risk Evaluation Report (PBRER), Risk Management Plan (RMP), and regulatory safety decision is built on information collected from different sources. These sources may include healthcare professionals, patients, clinical trials, literature, spontaneous reports, digital channels, partners, and regulatory authorities. 

However, collecting safety information is only the beginning. The quality, completeness, consistency, accuracy, and timeliness of that information determine how effectively it can be assessed and used. 

Poor-quality data can lead to incomplete case assessments, inaccurate signal detection, delayed reporting, duplicated cases, incorrect safety conclusions, and ultimately ineffective risk minimization. 

Therefore, data quality is not simply a data-management responsibility—it is a core component of patient safety and an essential element of an effective pharmacovigilance system. 

1. What Does Data Quality Mean in Pharmacovigilance?

Data quality in pharmacovigilance refers to the extent to which safety information is accurate, complete, consistent, timely, relevant, and fit for its intended purpose. 

For PV professionals, high-quality data should allow the organization to answer critical questions such as: 

• Who experienced the event?  

• What medicinal product was involved?  

• What happened?  

• When did it happen?  

• What was the outcome?  

• What treatment was provided?  

• Was the product discontinued or continued?  

• Were there relevant medical conditions or concomitant medications?  

• Can the case be medically assessed?  

• Can the case be identified as a valid ICSR?  

• Can the information support signal detection and benefit-risk assessment?  

A case may technically be received within the required reporting timeline but still have poor data quality if important information is missing, incorrectly entered, inconsistently coded, or not medically verified. 

This is why timeliness alone does not equal quality. 

2. The Critical Dimensions of PV Data Quality

Data quality is multidimensional. A robust PV system should monitor several key characteristics. 

2.1 Accuracy 

Information should accurately represent what was reported or documented. 

For example, incorrect entry of: 

• Patient age  

• Date of onset  

• Seriousness criteria  

• Product name  

• Dose  

• Route of administration  

• Laboratory values  

• Clinical outcome  

can directly affect medical assessment and downstream safety analysis. 

Accuracy also requires appropriate verification when information is unclear or contradictory. 

2.2 Completeness 

A high-quality case contains as much relevant information as reasonably available. 

Completeness is particularly important because missing information can limit: 

• Causality assessment  

• Seriousness assessment  

• Expectedness assessment  

• Clinical evaluation  

• Signal detection  

• Aggregate analysis  

For example, knowing that a patient developed an adverse event is useful, but additional information about the patient’s medical history, concomitant medications, laboratory results, treatment, and outcome may significantly change the interpretation of the case. 

Therefore, follow-up is an important data-quality activity, not merely an administrative task. 

2.3 Consistency 

Data should remain consistent across: 

• Source documents  

• Safety databases  

• Follow-up information  

• Regulatory submissions  

• Aggregate reports  

• Internal tracking systems  

For example, if the source document indicates that an event occurred on 10 August but the safety database records 10 September, this discrepancy may affect the assessment of the case and potentially the reporting timeline. 

Consistency checks and reconciliation activities help identify such discrepancies. 

2.4 Timeliness 

Safety information must be processed within applicable regulatory and procedural timelines. 

Delays can affect: 

• ICSR submission  

• Follow-up  

• Signal detection  

• Aggregate reporting  

• Regulatory responses  

• Safety communications  

Timeliness is therefore both a compliance requirement and a data-quality characteristic. 

2.5 Validity and Traceability 

PV data should be supported by appropriate source information and should remain traceable throughout its lifecycle. 

A PV professional should be able to understand: 

Where did the information come from? → Who processed it? → What changes were made? → Why were they made? → What was submitted or reported? 

Maintaining this traceability supports data integrity, inspection readiness, and confidence in safety outputs. 

3. Why Does Data Quality Matter for Patient Safety?

The ultimate purpose of pharmacovigilance is to protect patients. 

Consider a simple example: 

A company receives multiple reports of an adverse event associated with a medicinal product. However, the reports contain inconsistent product names, incomplete event descriptions, missing exposure information, and inaccurate dates. 

The underlying safety issue may exist, but poor-quality data can make it difficult to identify. 

This illustrates an important principle: 

A safety signal can only be as reliable as the data supporting it. 

High-quality data helps PV teams recognize meaningful patterns and distinguish potential signals from reporting noise. 

It also supports more reliable benefit-risk evaluations and enables appropriate regulatory and risk-minimization actions. 

4. Data Quality Across the ICSR Lifecycle

Data quality should be managed throughout the entire ICSR lifecycle rather than checked only at the end. 

Step 1: Case Intake 

The quality process begins when a safety report is received. 

The intake team should ensure that relevant information is captured from the original source without introducing unnecessary interpretation or alteration. 

Important considerations include: 

• Source identification  

• Receipt date  

• Reporter information  

• Patient information  

• Suspect product  

• Adverse event information  

• Initial seriousness information  

• Source documentation  

Early identification of missing information can also facilitate timely follow-up. 

Step 2: Case Triage and Validation 

The case should be assessed against applicable requirements to determine whether it constitutes a valid ICSR. 

The minimum information required for a valid case generally includes: 

1. An identifiable patient  

1. An identifiable reporter  

1. A suspect medicinal product  

1. A suspected adverse reaction  

If essential information is missing, the case may require clarification or follow-up. 

Poor triage can result in either missed reportable cases or inappropriate processing of non-valid reports. 

Step 3: Data Entry and Coding 

Once the case is validated, information is entered into the safety database. 

This stage requires careful attention to: 

• MedDRA coding  

• Product coding  

• Dates  

• Dose and frequency  

• Route of administration  

• Indication  

• Medical history  

• Concomitant medications  

• Laboratory results  

• Seriousness criteria  

• Outcome  

• Dechallenge/rechallenge information  

Standardized coding is particularly important because aggregate analyses and signal detection rely heavily on structured data. 

Step 4: Medical Review 

Medical review provides an additional layer of data-quality control. 

The reviewer may identify: 

• Contradictions  

• Clinically implausible information  

• Missing important medical details  

• Incorrect event interpretation  

• Inappropriate seriousness classification  

• Relevant follow-up questions  

The objective is not to change the source information, but to ensure that the information is accurately represented and appropriately assessed. 

Step 5: Follow-Up 

Follow-up is one of the most important mechanisms for improving case quality. 

Depending on the case, PV teams may seek additional information regarding: 

• Diagnosis  

• Clinical course  

• Relevant investigations  

• Treatment  

• Patient outcome  

• Hospitalization  

• Risk factors  

• Concomitant medications  

• Exposure details  

• Dechallenge/rechallenge  

Follow-up should be targeted and medically meaningful, rather than simply collecting information for the sake of completeness. 

Step 6: Quality Control and Quality Review 

Quality control should verify that the processed case accurately reflects the available source information and applicable procedures. 

Checks may include: 

• Correct patient information  

• Correct product  

• Correct event coding  

• Correct seriousness  

• Correct dates  

• Correct regulatory criteria  

• Correct narrative  

• Correct assessment  

• Appropriate supporting documents  

• Appropriate submission information  

Quality review should be proportionate to the risk and complexity of the process. 

5. The Role of SOPs and Controlled Processes

Data quality cannot depend solely on individual employee diligence. 

Organizations should establish documented processes covering activities such as: 

• Case intake  

• ICSR processing  

• Data entry  

• Medical review  

• Follow-up  

• Quality control  

• Regulatory submission  

• Reconciliation  

• Duplicate management  

• Literature screening  

• Signal management  

• Aggregate reporting  

• Partner data exchange  

Standard Operating Procedures (SOPs) help establish consistent expectations and responsibilities. 

However, an SOP is only effective when employees understand it, follow it, and receive appropriate training. 

6. Roles and Responsibilities in Maintaining Data Quality

Data quality is a shared responsibility across the PV ecosystem. 

Pharmacovigilance Professionals 

PV professionals are responsible for ensuring that safety information is appropriately: 

• Received  

• Validated  

• Entered  

• Coded  

• Assessed  

• Followed up  

• Reviewed  

• Submitted  

• Documented  

They should also identify recurring quality issues and escalate them when necessary. 

Local PV Teams and LPPVs 

Local PV personnel play an important role in ensuring that country-specific safety information is captured and managed appropriately. 

Their responsibilities may include: 

• Local case intake  

• Local literature monitoring  

• Authority correspondence  

• Follow-up with local sources  

• Local regulatory requirements  

• Oversight of local safety activities  

• Reconciliation with relevant partners or central teams  

Strong communication between local and global PV teams is essential to avoid information gaps. 

Medical Reviewers 

Medical reviewers contribute by ensuring that the clinical information is appropriately interpreted and that important medical inconsistencies or missing information are identified. 

Quality Assurance 

Quality Assurance (QA) provides independent oversight of the PV quality system. 

QA activities may include: 

• Audits  

• Inspections support  

• CAPA oversight  

• Quality-system assessments  

• Process monitoring  

Importantly, QA should not be viewed as the only function responsible for quality. Quality must be built into the process rather than inspected into the process afterward. 

Pharmacovigilance Management 

PV management has an important role in establishing: 

• Quality objectives  

• KPIs  

• Training requirements  

• Resources  

• Governance  

• Escalation mechanisms  

• Continuous improvement  

Management commitment is essential because data-quality problems may sometimes originate from broader process, system, workload, or training issues. 

7. Reconciliation: A Key Data-Quality Control

Reconciliation is particularly important when safety information exists across multiple systems or organizations. 

Examples include reconciliation between: 

• Safety database and regulatory submissions  

• PV and Medical Information  

• PV and Quality/Complaints  

• PV and Clinical teams  

• Company and distributors  

• Marketing Authorization Holder and service providers  

• Local and global PV databases  

The objective is to identify discrepancies and ensure that relevant safety information has been appropriately captured and processed. 

A reconciliation process should be clearly documented, with defined: 

• Frequency  

• Responsibilities  

• Data sources  

• Matching criteria  

• Discrepancy management  

• Escalation process  

• Documentation requirements  

8. Data Quality in Aggregate Safety Reporting

Data quality extends beyond individual cases. 

ICSR data feeds into aggregate safety documents such as: 

• PBRERs  

• PSURs, where applicable  

• DSURs  

• RMPs  

• Signal evaluation  

• Benefit-risk assessments  

If the underlying case data are inaccurate or incomplete, aggregate analyses may also be affected. 

For example, inconsistent coding of the same medical concept may fragment the data and potentially affect the identification of safety trends. 

Therefore, case-level data quality directly contributes to aggregate-level data quality. 

9. Regulatory Expectations and Inspection Readiness

Regulatory authorities expect Marketing Authorization Holders and other responsible organizations to maintain an effective pharmacovigilance system. 

Good PV data management should demonstrate: 

• Data integrity  

• Traceability  

• Timely processing  

• Appropriate documentation  

• Controlled procedures  

• Qualified personnel  

• Effective oversight  

• Appropriate quality controls  

• Continuous improvement  

During an inspection or audit, organizations may need to demonstrate not only what they do, but also how they know that they are doing it correctly. 

This is where metrics, reconciliations, quality checks, audits, CAPAs, training records, and documented oversight become important. 

10. Measuring Data Quality Through KPIs and Quality Metrics

What gets measured can be improved. 

Organizations can establish appropriate indicators to monitor data quality, such as: 

ICSR Quality Metrics 

• Percentage of cases requiring significant rework  

• Coding error rate  

• Duplicate rate  

• Missing-data rate  

• Narrative quality findings  

• Follow-up completion rate  

Timeliness Metrics 

• Case processing timelines  

• Submission compliance  

• Follow-up timelines  

• Reconciliation completion  

Process Metrics 

• Reconciliation discrepancies  

• CAPA recurrence  

• Audit findings  

• Training compliance  

• SOP deviations  

However, KPIs should not become a simple numbers exercise. 

A team achieving a high processing volume does not necessarily have a high-quality process. 

Quality metrics should be interpreted together with the context, complexity, and risk of the underlying work. 

11. Common Causes of Poor PV Data Quality

Several factors can contribute to poor-quality safety data. 

Human Factors 

• Insufficient training  

• High workload  

• Lack of experience  

• Inconsistent interpretation  

• Manual data-entry errors  

Process Factors 

• Unclear SOPs  

• Poor handovers  

• Undefined responsibilities  

• Ineffective escalation  

• Inadequate reconciliation  

System Factors 

• Database limitations  

• Poor system configuration  

• Duplicate records  

• Inadequate validation  

• Integration issues between systems  

Source Factors 

• Incomplete reporter information  

• Unclear medical descriptions  

• Delayed follow-up  

• Poor-quality source documents  

Understanding the root cause is critical. Repeatedly correcting the same error without addressing its underlying cause is not a sustainable quality strategy. 

12. How Can Organizations Improve PV Data Quality?

A strong data-quality strategy should combine prevention, detection, correction, and continuous improvement.

1. Standardize Processes

Clear procedures reduce variation between individuals and teams.

2. Strengthen Training

Training should cover not only what to enter, but also why the information matters for patient safety.

3. Use Risk-Based Quality Controls

Not every case requires the same level of review. Controls should reflect the potential impact and risk.

4. Improve Follow-Up Strategies

Focus follow-up questions on information that could materially affect the medical assessment or regulatory reporting.

5. Strengthen Reconciliation

Regular reconciliation can identify missing, duplicated, or inconsistent safety information.

6. Monitor Trends

Recurring errors should trigger investigation rather than repeated correction.

7. Apply Root Cause Analysis

When a quality issue occurs, ask: 

Why did it happen? 

Then continue asking: 

Why did the process allow it to happen? 

This can reveal whether the real issue is training, workload, system design, unclear ownership, or another process weakness.

8. Close the CAPA Loop

Corrective and Preventive Actions should address the root cause and be followed by effectiveness checks. 

13. From Reactive Quality Control to Proactive Data Quality

Traditional quality management can sometimes become reactive: 

Error → Detection → Correction 

A mature PV organization aims for: 

Risk Identification → Prevention → Monitoring → Early Detection → Improvement 

This shift is particularly important as PV systems become increasingly complex and incorporate information from multiple sources and digital channels. 

The goal should not simply be to reduce the number of errors found during quality review. 

The goal should be to design processes that make errors less likely to occur in the first place. 

14. The Future of Data Quality in Pharmacovigilance

The volume and complexity of safety information continue to increase. 

PV organizations are increasingly working with: 

• Large safety databases  

• Electronic health information  

• Literature  

• Digital platforms  

• Structured and unstructured data  

• Automated workflows  

• Artificial intelligence and machine-learning tools  

These technologies can support efficiency and improve data processing, but they also create new data-quality considerations. 

For example, automated systems still depend on: 

• Appropriate configuration  

• Reliable source data  

• Validated processes  

• Consistent terminology  

• Human oversight  

• Appropriate quality controls  

Technology can accelerate PV processes, but poor-quality input can still produce poor-quality output. 

The principle remains simple: 

Better technology does not eliminate the need for better data. 

Supporting Data Quality Across Pharmacovigilance Operations 

Maintaining high-quality safety data requires the right processes, expertise, and oversight across every stage of the pharmacovigilance lifecycle. Baupharma supports life sciences organizations through Pharmacovigilance services designed to strengthen data quality, regulatory compliance, and patient safety. 

By combining operational expertise with medical review, quality oversight, and regulatory knowledge, Baupharma helps organizations establish reliable and sustainable PV processes that support accurate safety assessments and informed decision-making. 

Key Takeaways 

• Data quality is fundamental to pharmacovigilance and patient safety.  

• Quality involves more than accuracy—it includes completeness, consistency, timeliness, validity, and traceability.  

• Data quality should be managed throughout the entire ICSR lifecycle.  

• Follow-up, reconciliation, quality control, and medical review are important mechanisms for improving data quality.  

• Data quality is a shared responsibility across PV professionals, LPPVs, medical reviewers, QA, management, partners, and other stakeholders.  

• Poor-quality case data can affect signal detection, aggregate reporting, and benefit-risk assessment.  

• KPIs and quality metrics should be used to identify trends and drive continuous improvement, not simply to measure productivity.  

• Effective organizations move from reactive error correction toward proactive quality management.  

• Ultimately, high-quality PV data supports better safety decisions and stronger protection of patients.